On August 21, Moderna, Inc. rose over 19% in regular trading. The stock rebounded after two consecutive sessions of profit-taking following its historic 177% single-day surge earlier this week.

On the news front, JPMorgan raised its price target on Moderna from $40 to $77, adding to a wave of Wall Street upgrades following the successful Phase III trial of the company's personalized mRNA cancer vaccine. Earlier upgrades included BofA Securities raising its target to $170 from $40 while upgrading to Neutral, Jefferies lifting its target to $150 from $60, Piper Sandler adjusting to $167 from $77, and Goldman Sachs moving to $120 from $67. The options market also showed bullish positioning, with a $25.35 million dual call-selling structure collecting premium at the 99.6% IV percentile and a $6.12 million far-month put sale indicating willingness to accumulate shares on dips.

The rebound comes after the stock shed approximately 23.5% in the prior session and an additional 3.27% in after-hours trading, as investors booked gains following the announcement that the INTerpath-001 Phase III trial of intismeran autogene combined with Keytruda met its primary endpoint of recurrence-free survival in melanoma patients.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)